Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prostatic penetration of meropenem after intravenous administration in patients undergoing transurethral resection of the prostate.

Yamada Y, Ikawa K, Nakamura K, Mitsui K, Narushima M, Hibi H, Ikeda K, Morikawa N, Honda N.

J Chemother. 2011 Jun;23(3):179-80. No abstract available.

PMID:
21742590
2.

Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.

Nishikawa G, Ikawa K, Nakamura K, Yamada Y, Zennami K, Mitsui K, Narushima M, Ikeda K, Morikawa N, Sumitomo M.

Int J Antimicrob Agents. 2013 Mar;41(3):267-71. doi: 10.1016/j.ijantimicag.2012.11.001. Epub 2013 Jan 11.

PMID:
23313536
3.

Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis.

Vlaar PJ, van Hulst M, Benne CA, Janssen WM.

Perit Dial Int. 2013 Nov-Dec;33(6):708-9. doi: 10.3747/pdi.2012.00155. No abstract available.

4.

Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.

Langan KM, Jacob J, Li J, Nation RL, Bellomo R, Howden B, Johnson PD.

Crit Care Resusc. 2014 Sep;16(3):190-6.

PMID:
25161021
5.

Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.

Isla A, Rodríguez-Gascón A, Trocóniz IF, Bueno L, Solinís MA, Maynar J, Sánchez-Izquierdo JA, Pedraz JL.

Clin Pharmacokinet. 2008;47(3):173-80.

PMID:
18307371
6.

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.

Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2003 Aug;23(8):988-91.

PMID:
12921245
7.

Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.

Kondo N, Ikawa K, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Ohge H, Morikawa N, Sueda T.

Pancreatology. 2014 Mar-Apr;14(2):95-9. doi: 10.1016/j.pan.2014.02.002. Epub 2014 Feb 12.

PMID:
24650961
8.

Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.

Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P, Moutschen M.

J Antimicrob Chemother. 2015 Jan;70(1):207-16. doi: 10.1093/jac/dku354. Epub 2014 Sep 12.

9.

Short versus long infusion of meropenem in very-low-birth-weight neonates.

Padari H, Metsvaht T, Kõrgvee LT, Germovsek E, Ilmoja ML, Kipper K, Herodes K, Standing JF, Oselin K, Lutsar I.

Antimicrob Agents Chemother. 2012 Sep;56(9):4760-4. doi: 10.1128/AAC.00655-12. Epub 2012 Jun 25.

10.

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.

Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR.

Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):85-8.

PMID:
1864280
11.

Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.

Bretonnière C, Jacqueline C, Caillon J, Guitton C, Le Mabecque V, Miégeville AF, Villers D, Potel G, Boutoille D.

J Antimicrob Chemother. 2010 Nov;65(11):2423-7. doi: 10.1093/jac/dkq334. Epub 2010 Sep 21.

12.

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS Jr.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):251-8. doi: 10.1016/j.diagmicrobio.2010.06.012. Epub 2010 Sep 18.

PMID:
20851549
13.

Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.

Jamal JA, Mat-Nor MB, Mohamad-Nor FS, Udy AA, Wallis SC, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2015 Jan;45(1):41-5. doi: 10.1016/j.ijantimicag.2014.09.009. Epub 2014 Oct 18.

PMID:
25455853
14.

Population pharmacokinetics of meropenem in burn patients.

Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim DS.

J Antimicrob Chemother. 2010 Nov;65(11):2428-35. doi: 10.1093/jac/dkq317. Epub 2010 Sep 3.

15.

Considerations of meropenem dosage for bacterial meningitis based on pharmacodynamics in cerebrospinal fluid.

Ikawa K, Morikawa N, Ikeda K, Tsumura R, Shibukawa M, Iida K, Kurisu K.

Int J Antimicrob Agents. 2008 Jul;32(1):96-8. doi: 10.1016/j.ijantimicag.2008.03.001. Epub 2008 Jun 6. No abstract available.

PMID:
18539005
16.
17.

Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.

Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W.

Int J Antimicrob Agents. 2011 Sep;38(3):231-6. doi: 10.1016/j.ijantimicag.2011.04.019. Epub 2011 Jul 2.

PMID:
21726984
18.
19.

Penetration of orally administered prulifloxacin into human prostate tissue.

Giberti C, Gallo F, Rosignoli MT, Ruggieri A, Barattè S, Picollo R, Dionisio P.

Clin Drug Investig. 2009;29(1):27-34. doi: 10.2165/0044011-200929010-00003.

PMID:
19067472
20.

Pharmacokinetic and pharmacodynamic properties of meropenem.

Nicolau DP.

Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S32-40. doi: 10.1086/590064. Review.

Items per page

Supplemental Content

Write to the Help Desk